4ANTMAN K, LAGAKOS S, DRAZEN J. Designing and funding clinical trials of novel therapies [J]. N Engl J Med, 2000, 324 (14): 1207-1238. 被引量：1
5LEVINE AM, TULPULE A. Clinical aspects and management of AIDS-related Kaposi's sarcoma [J]. Eur J Cancer, 2001, 37(10): 1288-1295. 被引量：1
6MARCHISONE C, BENELLI R, ALBINI A,et al. Inhibition of angiogenesis by class I interferons in models of Kaposi's sarcoma [J]. Int J Biol Markers, 1999, 14: 257-262. 被引量：1
2Kinlen L. In immunolgic factors, including AIDS. Sehotterdeld D,Fraumeni JF, eds. Cancer epidemiology and prevention, 2nd edn.New York, Oxford University Press, 1996. 532-545. 被引量：1
3IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 67. Lyon, IARC, 1996. 被引量：1
4CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR, 1987,36(S-1) : 1. 被引量：1
5CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR, 1993,41(RR-17) : 1. 被引量：1
6Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet,1998,351:1833-1839. 被引量：1
7Biggar RJ, Frisch M, Goedert J J, et al. Risk of cancer in children with AIDS. JAMA,2000,284 : 205 -209. 被引量：1
8Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HI-IV8 associated diseases, part 1 : epidemiology,environmental predispositions, clinical manifestations, and therapy.Lancet Infect Dis, 2002, 2:281-292. 被引量：1
9Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi' s sarcoma and non-Hodgkin' s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst, 2002, 94:1204-1210. 被引量：1
10Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumors in developed and developing countries. Eur J Cancer,2001,37: 1188-1201. 被引量：1
